Atossa Genetics Announces First Quarter 2017 Financial Results and Provides Company Update
(firmenpresse) - SEATTLE, WA -- (Marketwired) -- 05/11/17 -- Atossa Genetics, Inc. (NASDAQ: ATOS) today announced First Quarter ended March 31, 2017 financial results and provided an update on recent company developments.
Steve Quay, President and CEO, commented, "We are encouraged by our positive progress in advancing the endoxifen program with our ongoing Phase 1 endoxifen study and pleased that our fulvestrant microcatheter study is proceeding at Montefiore Medical Center. We look forward to completing our endoxifen Phase 1 study in the next quarter and commencing a Phase 2 study in the second half of 2017."
Atossa''s important recent developments include the following:
May 2017 - Atossa received second positive safety decision in Phase 1 topical endoxifen study.
May 2017 - Institutional Review Board approved continuation of fulvestrant microcatheter Phase 2 study at Montefiore Medical Center.
April 2017 - Atossa received positive interim review from independent safety committee in Phase 1 topical endoxifen study.
April 2017 - Atossa enrolled first cohort of eight subjects in endoxifen study.
March 2017 - Atossa raised approximately $4.4 million in gross proceeds in a public offering.
March 2017 - Atossa opened its endoxifen Phase 1 clinical study.
Atossa plans to commence a Phase 2 clinical study of endoxifen in the second half of 2017.
We are in the research and development phase and do not generate revenue.
Operating expenses: Total operating expenses were approximately $1.7 million for the three months ended March 31, 2017, consisting of general and administrative (G&A) expenses of approximately $1.1 million and R&D expenses of approximately $544,000. Operating expenses for the three months ended March 31, 2017 decreased approximately $641,000, or 27.5%, from approximately $2.3 million for the three months ended March 31, 2016, which consisted of G&A expenses of approximately $2.2 million, and R&D expenses of approximately $150,000.
The Company recorded a net loss of $1.7 million, for the three months ended March 31, 2017, as compared to a net loss of $2.3 million for the three months ended March 31, 2016.
Atossa Genetics, Inc., is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit .
Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, results of clinical studies, the safety and efficacy of Atossa''s products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others, such as patent rights, and other risks detailed from time to time in Atossa''s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
Atossa Genetics Company Contact:
Atossa Genetics, Inc.
Kyle Guse
CFO and General Counsel
(O) 800-351-3902
Investor Relations Contact
Scott Gordon
CorProminence LLC
377 Oak Street
Concourse 2
Garden City, NY 11530
Office: 516.222.2560
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 11.05.2017 - 15:30 Uhr
Sprache: Deutsch
News-ID 1504135
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
SEATTLE, WA
Phone:
Kategorie:
Biotech
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 371 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Atossa Genetics Announces First Quarter 2017 Financial Results and Provides Company Update
"
steht unter der journalistisch-redaktionellen Verantwortung von
Atossa Genetics, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
